{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T22:24:58Z","timestamp":1795040698626,"version":"4.10.2"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s13045-018-0685-2","type":"journal-article","created":{"date-parts":[[2018,12,26]],"date-time":"2018-12-26T20:51:47Z","timestamp":1545857507000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":68,"title":["Management of adverse events associated with bosutinib treatment of chronic-phase chronic myeloid leukemia: expert panel review"],"prefix":"10.1186","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8636-1071","authenticated-orcid":false,"given":"Jorge E.","family":"Cortes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane F.","family":"Apperley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"DeAngelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael W.","family":"Deininger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vamsi K.","family":"Kota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Rousselot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Gambacorti-Passerini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,12,27]]},"reference":[{"key":"685_CR1","unstructured":"Pfizer. BOSULIF (bosutinib). Prescribing information (updated December 2017). \n                    https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/203341s009lbl.pdf\n                    \n                  . Accessed 7 June 2018."},{"key":"685_CR2","unstructured":"European Medicines Agency. BOSULIF (bosutinib). Summary of product characteristics (updated May 2018). \n                    http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002373\/WC500141721.pdf\n                    \n                  . Accessed 7 June 2018."},{"key":"685_CR3","doi-asserted-by":"publisher","first-page":"4567","DOI":"10.1182\/blood-2011-05-355594","volume":"118","author":"JE Cortes","year":"2011","unstructured":"Cortes JE, Kantarjian HM, Br\u00fcmmendorf TH, Kim DW, Turkina AG, Shen ZX, et al. Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib. Blood. 2011;118:4567\u201376.","journal-title":"Blood"},{"key":"685_CR4","doi-asserted-by":"publisher","first-page":"3403","DOI":"10.1182\/blood-2011-11-390120","volume":"119","author":"HJ Khoury","year":"2012","unstructured":"Khoury HJ, Cortes JE, Kantarjian HM, Gambacorti-Passerini C, Baccarani M, Kim DW, et al. Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and\/or nilotinib therapy failure. Blood. 2012;119:3403\u201312.","journal-title":"Blood"},{"key":"685_CR5","doi-asserted-by":"publisher","first-page":"3486","DOI":"10.1200\/JCO.2011.38.7522","volume":"30","author":"JE Cortes","year":"2012","unstructured":"Cortes JE, Kim DW, Kantarjian HM, Br\u00fcmmendorf TH, Dyagil I, Griskevicius L, et al. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial. J Clin Oncol. 2012;30:3486\u201392.","journal-title":"J Clin Oncol"},{"key":"685_CR6","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1200\/JCO.2017.74.7162","volume":"36","author":"JE Cortes","year":"2018","unstructured":"Cortes JE, Gambacorti-Passerini C, Deininger MW, Mauro MJ, Chuah C, Kim DW, et al. Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE trial. J Clin Oncol. 2018;36:231\u20137.","journal-title":"J Clin Oncol"},{"key":"685_CR7","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.3324\/haematol.2017.171249","volume":"103","author":"C Gambacorti-Passerini","year":"2018","unstructured":"Gambacorti-Passerini C, Cortes JE, Lipton JH, Kantarjian HM, Kim DW, Schafhausen P, et al. Safety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia over a five-year period: final results of a phase I\/II study. Haematologica. 2018;103:1298\u2013307.","journal-title":"Haematologica"},{"key":"685_CR8","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1002\/ajh.24536","volume":"91","author":"JE Cortes","year":"2016","unstructured":"Cortes JE, Khoury HJ, Kantarjian HM, Lipton JH, Kim DW, Schafhausen P, et al. Long-term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and\/or nilotinib. Am J Hematol. 2016;91:1206\u201314.","journal-title":"Am J Hematol"},{"key":"685_CR9","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1111\/bjh.13108","volume":"168","author":"TH Br\u00fcmmendorf","year":"2015","unstructured":"Br\u00fcmmendorf TH, Cortes JE, de Souza CA, Guilhot F, Duvillie L, Pavlov D, et al. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial. Br J Haematol. 2015;168:69\u201381.","journal-title":"Br J Haematol"},{"key":"685_CR10","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1002\/ajh.23728","volume":"89","author":"C Gambacorti-Passerini","year":"2014","unstructured":"Gambacorti-Passerini C, Br\u00fcmmendorf TH, Kim DW, Turkina AG, Masszi T, Assouline S, et al. Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: minimum 24-month follow-up. Am J Hematol. 2014;89:732\u201342.","journal-title":"Am J Hematol"},{"key":"685_CR11","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1200\/JCO.2013.53.0204","volume":"32","author":"V Prasad","year":"2014","unstructured":"Prasad V, Massey PR, Fojo T. Oral anticancer drugs: how limited dosing options and dose reductions may affect outcomes in comparative trials and efficacy in patients. J Clin Oncol. 2014;32:1620\u20139.","journal-title":"J Clin Oncol"},{"key":"685_CR12","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.blre.2018.01.004","volume":"32","author":"BC Medeiros","year":"2018","unstructured":"Medeiros BC, Possick J, Fradley M. Cardiovascular, pulmonary, and metabolic toxicities complicating tyrosine kinase inhibitor therapy in chronic myeloid leukemia: strategies for monitoring, detecting, and managing. Blood Rev. 2018;32:289\u201399.","journal-title":"Blood Rev"},{"key":"685_CR13","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/nrclinonc.2016.139","volume":"14","author":"G Rosti","year":"2017","unstructured":"Rosti G, Castagnetti F, Gugliotta G, Baccarani M. Tyrosine kinase inhibitors in chronic myeloid leukaemia: which, when, for whom? Nat Rev Clin Oncol. 2017;14:141\u201354.","journal-title":"Nat Rev Clin Oncol"},{"key":"685_CR14","unstructured":"Novartis. GLEEVEC (imatinib mesylate). Prescribing information (updated July 2018). Available at \n                    https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/021588s053lbl.pdf\n                    \n                  . Accessed 17 Sept 2018."},{"key":"685_CR15","unstructured":"Novartis. TASIGNA (nilotinib). Prescribing information (updated July 2018). Available at \n                    https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/022068s029lbl.pdf\n                    \n                  . Accessed 17 Sept 2018."},{"key":"685_CR16","unstructured":"Bristol-Myers Squibb. SPRYCEL (dasatinib). Prescribing information (updated November 2017). Available at \n                    https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/021986s020lbl.pdf\n                    \n                  . Accessed 16 Aug 2018."},{"key":"685_CR17","unstructured":"ARIAD Pharmaceuticals. ICLUSIG (ponatinib). Prescribing information (updated December 2017). Available at \n                    https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/203469s027s028lbl.pdf\n                    \n                  . Accessed 17 Sept 2018."},{"key":"685_CR18","unstructured":"Incyte Biosciences UK Ltd. ICLUSIG (ponatinib). Summary of product characteristics (updated August 2018). Available at \n                    http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002695\/WC500145646.pdf\n                    \n                  . Accessed 20 Sept 2018."},{"key":"685_CR19","doi-asserted-by":"publisher","first-page":"iv41","DOI":"10.1093\/annonc\/mdx219","volume":"28","author":"A Hochhaus","year":"2017","unstructured":"Hochhaus A, Saussele S, Rosti G, Mahon FX, Janssen J, Hjorth-Hansen H, et al. Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28:iv41\u201351.","journal-title":"Ann Oncol"},{"key":"685_CR20","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1097\/PPO.0000000000000165","volume":"22","author":"PA Pophali","year":"2016","unstructured":"Pophali PA, Patnaik MM. The role of new tyrosine kinase inhibitors in chronic myeloid leukemia. Cancer J. 2016;22:40\u201350.","journal-title":"Cancer J"},{"issue":"Suppl 1","key":"685_CR21","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1053\/j.seminoncol.2011.01.016","volume":"38","author":"JY Blay","year":"2011","unstructured":"Blay JY, von Mehren M. Nilotinib: a novel, selective tyrosine kinase inhibitor. Semin Oncol. 2011;38(Suppl 1):S3\u20139.","journal-title":"Semin Oncol"},{"key":"685_CR22","doi-asserted-by":"publisher","first-page":"14741","DOI":"10.1021\/ja405939x","volume":"135","author":"YL Lin","year":"2013","unstructured":"Lin YL, Roux B. Computational analysis of the binding specificity of Gleevec to Abl, c-kit, Lck, and c-Src tyrosine kinases. J Am Chem Soc. 2013;135:14741\u201353.","journal-title":"J Am Chem Soc"},{"key":"685_CR23","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1182\/blood.V128.22.1921.1921","volume":"128","author":"V Kota","year":"2016","unstructured":"Kota V, Br\u00fcmmendorf T, Gambacorti-Passerini C, Cortes J, Lipton J, Kantarjian H, et al. Efficacy and safety following bosutinib dose reduction in patients with Philadelphia chromosome-positive chronic myeloid leukemia. Blood. 2016;128:1921.","journal-title":"Blood"},{"key":"685_CR24","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1182\/blood-2018-99-110543","volume":"132","author":"TH Br\u00fcmmendorf","year":"2018","unstructured":"Br\u00fcmmendorf TH, Gambacorti-Passerini C, Hochhaus A, Lipton JH, Kota V, Deininger MW, et al. Efficacy and safety following dose reduction of bosutinib or imatinib in patients with newly diagnosed chronic myeloid leukemia: analysis of the phase 3 BFORE trial. Blood. 2018;132:3005.","journal-title":"Blood"},{"key":"685_CR25","first-page":"2899","volume":"130","author":"M Garrett","year":"2017","unstructured":"Garrett M, Knight B, Cortes J, Deininger M. Optimizing dose of bosutinib to minimize adverse events while maintaining efficacy in patients with newly diagnosed chronic myelogenous leukemia. Blood. 2017;130:2899.","journal-title":"Blood"},{"key":"685_CR26","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1002\/ajh.24034","volume":"90","author":"C Gambacorti-Passerini","year":"2015","unstructured":"Gambacorti-Passerini C, Kantarjian HM, Kim DW, Khoury HJ, Turkina AG, Br\u00fcmmendorf TH, et al. Long-term efficacy and safety of bosutinib in patients with advanced leukemia following resistance\/intolerance to imatinib and other tyrosine kinase inhibitors. Am J Hematol. 2015;90:755\u201368.","journal-title":"Am J Hematol"},{"key":"685_CR27","unstructured":"National Comprehensive Cancer Network (NCCN Guidelines\u00ae). Chronic myeloid leukemia. Available at \n                    https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/cml.pdf\n                    \n                   (password restricted). Accessed 15 Aug 2018."},{"key":"685_CR28","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1182\/blood-2013-07-513937","volume":"123","author":"HM Kantarjian","year":"2014","unstructured":"Kantarjian HM, Cortes JE, Kim DW, Khoury HJ, Br\u00fcmmendorf TH, Porkka K, et al. Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors. Blood. 2014;123:1309\u201318.","journal-title":"Blood"},{"key":"685_CR29","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1093\/annonc\/mdy019","volume":"29","author":"HJ Khoury","year":"2018","unstructured":"Khoury HJ, Gambacorti-Passerini C, Br\u00fcmmendorf TH. Practical management of toxicities associated with bosutinib in patients with Philadelphia chromosome-positive chronic myeloid leukemia. Ann Oncol. 2018;29:578\u201387.","journal-title":"Ann Oncol"},{"key":"685_CR30","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/j.clml.2017.06.001","volume":"17","author":"JE Cortes","year":"2017","unstructured":"Cortes JE, Gambacorti-Passerini C, Kim DW, Kantarjian HM, Lipton JH, Lahoti A, et al. Effects of bosutinib treatment on renal function in patients with Philadelphia chromosome-positive leukemias. Clin Lymphoma Myeloma Leuk. 2017;17:684\u201395 e6.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"685_CR31","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.clml.2015.12.001","volume":"16","author":"E Vidal-Petiot","year":"2016","unstructured":"Vidal-Petiot E, Rea D, Serrano F, Stehle T, Gardin C, Rousselot P, et al. Imatinib increases serum creatinine by inhibiting its tubular secretion in a reversible fashion in chronic myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2016;16:169\u201374.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"685_CR32","doi-asserted-by":"crossref","unstructured":"Cortes JE, Khoury HJ, Kantarjian H, Br\u00fcmmendorf TH, Mauro MJ, Matczak E, et al. Long-term evaluation of cardiac and vascular toxicity in patients with Philadelphia chromosome-positive leukemias treated with bosutinib. Am J Hematol. 2016;91:606\u201316.","DOI":"10.1002\/ajh.24360"},{"key":"685_CR33","doi-asserted-by":"crossref","unstructured":"Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016;37:2315\u201381.","DOI":"10.1093\/eurheartj\/ehw106"},{"key":"685_CR34","doi-asserted-by":"publisher","first-page":"S49","DOI":"10.1161\/01.cir.0000437741.48606.98","volume":"129","author":"DC Goff Jr","year":"2014","unstructured":"Goff DC Jr, Lloyd-Jones DM, Bennett G, Coady S, D'Agostino RB, Gibbons R, et al. 2013 ACC\/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129:S49\u201373.","journal-title":"Circulation"},{"key":"685_CR35","doi-asserted-by":"publisher","first-page":"e147","DOI":"10.1016\/j.jacc.2013.05.019","volume":"62","author":"CW Yancy","year":"2013","unstructured":"Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, et al. 2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;62:e147\u2013239.","journal-title":"J Am Coll Cardiol"},{"key":"685_CR36","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1161\/CIR.0b013e31829e8807","volume":"128","author":"CW Yancy","year":"2013","unstructured":"Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, et al. 2013 ACCF\/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on practice guidelines. Circulation. 2013;128:1810\u201352.","journal-title":"Circulation"}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-018-0685-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13045-018-0685-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-018-0685-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,12,26]],"date-time":"2019-12-26T19:23:25Z","timestamp":1577388205000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-018-0685-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["685"],"URL":"https:\/\/doi.org\/10.1186\/s13045-018-0685-2","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"23 October 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 December 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"J.E.C. has received consultancy fees from Pfizer, Novartis, Forma Therapeutics, Daiichi, and Astellas, and research funding from Pfizer, Novartis, Forma Therapeutics, Daiichi, and Astellas.J.F.A. has received honoraria from ARIAD, Bristol-Myers Squibb, Incyte, MSD, Novartis, and Pfizer, and has received research funding from ARIAD, Novartis and Pfizer.D.J.D. has served in a consulting or advisory role for Amgen, ARIAD, Bristol-Myers Squibb, Incyte, Novartis, and Pfizer, and has received research funding from ARIAD.M.W.D. has served in a consulting or advisory role for ARIAD, Bristol-Myers Squibb, Incyte, Novartis, and Pfizer; has received travel, accommodations, or other expense reimbursements from ARIAD, Bristol-Myers Squibb, CTI BioPharma, Novartis, and Pfizer; has provided expert testimony for Bristol-Myers Squibb; has received honoraria from ARIAD, Bristol-Myers Squibb, CTI BioPharma, Incyte, Novartis, and Pfizer; and has received research funding from ARIAD, Bristol-Myers Squibb, Celgene, Incyte, and Novartis.V.K.K. has received consultancy fees from ARIAD, Pfizer, Xcenda, Bristol-Myers Squibb, and Incyte.P.R. reports research funding from Pfizer.C.G.-P. has served in an advisory role to Bristol-Myers Squibb and Pfizer and has received research funding from ARIAD.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"143"}}